Posted by Michael Wonder on 10 Feb 2022
Bayer receives U.S. FDA fast track designation for asundexian stroke program
10 February 2022 - Bayer today announced that the U.S. FDA has granted fast track designation for its investigational drug asundexian (BAY2433334) as a potential treatment for secondary prevention in patients with a non-cardioembolic ischaemic stroke.
Asundexian is an oral inhibitor of Factor XIa that Bayer is developing as a potential treatment for secondary prevention in patients with a non-cardioembolic ischaemic stroke as well as for two additional conditions: atrial fibrillation (irregular heartbeat) and recent myocardial infarction (heart attack).
